Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Retained Earnings (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Retained Earnings readings, the most recent being $1.2 million for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.57% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 100.57% increase, with the full-year FY2025 number at $1.2 million, up 100.57% from a year prior.
  • Retained Earnings hit $1.2 million in Q4 2025 for Fennec Pharmaceuticals, up from -$224.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $215.6 million in Q3 2023 to a low of -$224.6 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$179.1 million (2021), compared with a mean of -$110.2 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 209.81% in 2023 and later plummeted 17773.45% in 2024.
  • Fennec Pharmaceuticals' Retained Earnings stood at $1.2 million in 2021, then changed by 0.0% to $1.2 million in 2022, then changed by 0.0% to $1.2 million in 2023, then plummeted by 17773.45% to -$219.7 million in 2024, then skyrocketed by 100.57% to $1.2 million in 2025.
  • The last three reported values for Retained Earnings were $1.2 million (Q4 2025), -$224.6 million (Q3 2025), and -$224.0 million (Q2 2025) per Business Quant data.